This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): SLV313
Description: SLV313 is a dopamine D2/D3 receptor antagonist and serotonin 5-HT1A receptor agonist. It also has high affinity at D4 and 5-HT2B receptors, moderate affinity at 5-HT7 receptors, weak affinity at 5-HT2A receptors, and little to no affinity at 5-HT4, 5-HT6, alpha1, and alpha2, H1, M1, M4, 5-HT3 receptors and the 5-HT transporter.
Deal Structure: In April 2004, Solvay Pharmaceuticals announced that it signed extensive agreements with Wyeth Pharmaceuticals to co-develop and co-commercialize several central nervous system (CNS) compounds. The compounds in development include SLV313 and SLV314, which are a worldwide collaboration.
In February 2008, Wyeth Pharmaceuticals announced the end of its collaboration agreements with Solvay Pharmaceuticals for the development and commercialization of bifeprunox, as well as SLV 313 and SLV314. All development and commercialization rights in North America for bifeprunox as well as global rights for the other compounds will now revert to Solvay Pharmaceuticals.
In September 2009, Solvay announced that its Board of Directors has decided to sell its entire pharmaceutical business to Abbott for a total Entreprise Value of about EUR 5.2 billion. This includes a purchase price of EUR 4.5 billion in cash and additional potential payments of up to EUR 300 million if certain milestones are...See full deal structure in Biomedtracker
Additional information available to subscribers only: